1115 related articles for article (PubMed ID: 16802350)
1. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
Inman RD; Maksymowych WP;
J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E;
Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
10. [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis].
Huang F; Zhang J; Zheng Y; Xu JH; Li XF; Wu HX; Chen ZW; Zhao Z; Zhang YM
Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1043-7. PubMed ID: 22333175
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
14. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
Dougados M; Luo MP; Maksymowych WP; Chmiel JJ; Chen N; Wong RL; Davis JC; van der Heijde D;
Arthritis Rheum; 2008 Apr; 59(4):553-60. PubMed ID: 18383418
[TBL] [Abstract][Full Text] [Related]
16. Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics.
Maksymowych WP; Gooch K; Dougados M; Wong RL; Chen N; Kupper H; van der Heijde D
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):826-34. PubMed ID: 20535793
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
18. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study).
Navarro-Sarabia F; Fernández-Sueiro JL; Torre-Alonso JC; Gratacos J; Queiro R; Gonzalez C; Loza E; Linares L; Zarco P; Juanola X; Román-Ivorra J; Martín-Mola E; Sanmartí R; Mulero J; Diaz G; Armendáriz Y; Collantes E
Rheumatology (Oxford); 2011 Oct; 50(10):1828-37. PubMed ID: 21700683
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
Maksymowych WP; Rahman P; Shojania K; Olszynski WP; Thomson GT; Ballal S; Wong RL; Inman RD;
J Rheumatol; 2008 Oct; 35(10):2030-7. PubMed ID: 18785308
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]